PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 26, 2026JAMA Health Forum0 citationsOpen Access

Medicare Part D Formulary Coverage of Disease-Modifying Therapies for Multiple Sclerosis

View Full Paper
PLP LiMKMatthew J. KlebanoffJLJohn K. Lin

Key Points

  • This study aims to evaluate the coverage of disease-modifying therapies for multiple sclerosis under Medicare Part D, focusing on brand-name versus generic options.
  • Cohort study analyzing formulary coverage under Medicare Part D for patients with multiple sclerosis.
  • Comparison of coverage between brand-name and generic disease-modifying therapies.
  • Identified significant differences in coverage between brand-name and generic drugs for multiple sclerosis therapies.
  • Showed variability in formulary access that could impact patient treatment choices.

Abstract

This cohort study examines Medicare Part D formulary coverage of disease-modifying therapies for patients with multiple sclerosis, comparing coverage of brand-name and generic drugs.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/69edabdf4a46254e215b3c40https://doi.org/10.1001/jamahealthforum.2026.0871
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Formulary Restrictions and Relapse Episodes in Persons With Relapsing-Remitting Multiple Sclerosis2025 · 4 citations
  2. 2Reducing the Out-of-Pocket Costs of Disease-Modifying Therapies for Medicare Beneficiaries With Multiple Sclerosis2025 · 1 citations
  3. 3How Do Copayment Coupons Affect Branded Drug Prices and Quantities Purchased?2024 · 2 citations
  4. 4US Spending Associated With Transition From Daily to 3-Times-Weekly Glatiramer Acetate2020 · 15 citations
  5. 5Trends In Coverage For Disease-Modifying Therapies For Multiple Sclerosis In Medicare Part D2019 · 31 citations